Spruce Biosciences reports Q4/FY2021 net loss of $9.2M/$42.3M; cash $121.4M

SPRUCE BIOSCIENCES, INC.

Cash, cash equivalents and investments of $121.4M as of Dec 31, 2021; expected to fund operations into Q2 2024.
R&D expenses for FY2021: $30.7M, up from $23.9M in 2020; net loss widened to $42.3M from $29.5M.
Appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer in March 2022; he previously served at 89bio.
Topline safety data from Cohort 1 of Phase 2 pediatric classic CAH study expected by 1H 2023; PCOS Phase 2 topline also by 1H 2023.
CAHmelia-203 (adult classic CAH, poor disease control) topline by 2H 2023; CAHmelia-204 (good disease control) by 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.